UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,393,140 shares of the medical research company's stock after purchasing an additional 167,057 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.77% of IQVIA worth $273,766,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Howard Capital Management Inc. increased its stake in IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares in the last quarter. Harbor Investment Advisory LLC lifted its holdings in shares of IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares in the last quarter. Magnolia Capital Advisors LLC lifted its holdings in shares of IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after purchasing an additional 74 shares in the last quarter. New York Life Investment Management LLC lifted its holdings in shares of IQVIA by 0.4% during the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock valued at $4,537,000 after purchasing an additional 81 shares in the last quarter. Finally, Zions Bancorporation N.A. lifted its holdings in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.
IQVIA Stock Performance
IQV traded down $1.08 during midday trading on Friday, reaching $136.96. The company had a trading volume of 2,248,506 shares, compared to its average volume of 1,560,203. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a 50-day moving average of $155.33 and a two-hundred day moving average of $183.37. The company has a market cap of $23.69 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the previous year, the company earned $2.54 EPS. IQVIA's revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the company. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Mizuho lowered their price target on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Finally, Stifel Nicolaus cut their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $228.14.
Read Our Latest Research Report on IQVIA
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
